Abstract
Monoclonal antibodies and bispecific antibody constructs hold considerable promise in improving the outcomes of patients with acute lymphoblastic leukemia (ALL). Antibody-drug conjugates such as inotuzumab ozogamicin and the bispecific T-cell engager blinatumomab represent novel antibody constructs that have shown substantial clinical activity in ALL. Although most studies have focused on the use of these agents in the salvage setting, incorporation of these antibodies into the frontline regimens is imperative to improve long-term survival for patients with ALL and to increase the cure rates of adult ALL to the levels achieved in the pediatric population.
Original language | English (US) |
---|---|
Pages (from-to) | 574-578 |
Number of pages | 5 |
Journal | American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting |
Issue number | 38 |
DOIs | |
State | Published - May 23 2018 |
ASJC Scopus subject areas
- General Medicine